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A canine model of Glycogen storage disease type Ia (GSDIa) is described. Aﬀected dogs are homozygous for a previously described
M121I mutation resulting in a deﬁciency of glucose-6-phosphatase-α. Metabolic, clinicopathologic, pathologic, and clinical
manifestations of GSDIa observed in this model are described and compared to those observed in humans. The canine model
shows more complete recapitulation of the clinical manifestations seen in humans including “lactic acidosis”, larger size, and
longer lifespan compared to other animal models. Use of this model in preclinical trials of gene therapy is described and brieﬂy
compared to the murine model. Although the canine model oﬀers a number of advantages for evaluating potential therapies for
GSDIa, there are also some signiﬁcant challenges involved in its use. Despite these challenges, the canine model of GSDIa should
continue to provide valuable information about the potential for generating curative therapies for GSDIa as well as other genetic
hepatic diseases.
1.Introduction
Glycogen storage disease type Ia (GSDIa; von Gierke disease;
MIM 232200) is an inherited metabolic disorder resulting
from a deﬁciency in the enzyme glucose 6-phosphatase-
α (G6Pase; EC 3.1.3.9). Without G6Pase activity, all
endogenous glucose production is impaired as this critical
enzyme catalyzes the ﬁnal step of both gluconeogenesis
and glycogenolysis. Consequently, circulating blood glucose
levels cannot be increased in response to positive glucoregu-
latory stimuli leading to a condition characterized by fasting
hypoglycemia, as well as accumulation of glycogen and fat,
particularly within liver and kidney tissues [1–3]. Shunting
of glucose-6-phosphate (G6P) into alternative metabolic
pathways results in lactic acidosis, hypertriglyceridemia, and
hyperuricemia [1–3].
Current therapy is directed at preventing hypoglycemia
through sustained provision of glucose via continuous or
frequent feedings or consumption of uncooked starches
[4–8]. These types of palliative dietary therapy have had
a profound impact on morbidity and mortality, allowing
most aﬀected individuals to have near normal growth,2 Journal of Biomedicine and Biotechnology
pubertal development, and subsequent survival to adult-
hood. However, the underlying pathology remains untreated
and the therapy can have other metabolic consequences
such as hyperinsulinemia and excessive caloric intake from
continuous glucose delivery [9]. In addition, long-term
complications remain a problem in individuals with GSDIa
[10–13]. Therefore, a search for additional or alternative
therapeutic approaches geared to help improve quality of life
and long-term outcomes for patients with GSDIa continues.
Gene therapy or stem cell therapy is expected, by correcting
the underlying problem of G6Pase deﬁciency, to prevent the
complications of GSDIa and the undesired consequences of
current therapies, thereby improving the prognosis for such
patients. Evaluation of the potential safety and eﬃcacy of
suchtherapiesrequirestestinginappropriateanimalmodels.
A murine model of GSDIa has been generated which
manifests most of the clinical signs and much of the pathol-
ogy associated with the human condition [14, 15]. However,
this model has a few drawbacks including small size of the
animals and a short lifespan. In addition, there are also some
key diﬀerences between the disease manifestation in humans
and the GSDIa knockout mouse. First, mice with GSDIa
have not been shown to develop lactic acidosis until they
are at least 6 weeks of age and the diﬀerence in blood lactate
concentrationsbetweenwildtypeandaﬀected mice reported
after this age is mild compared to that observed in human
patients [14–16]. Secondly, in contrast to humans, adenoma
formation at equivalently young ages is uncommon. Thus,
while this model has proven very useful in furthering our
understanding of GSDIa, an animal model with physiology
and long-term consequences closer to what is observed in
humans is advantageous before the experimental techniques
can safely be attempted in humans.
A naturally occurring canine model has been described
with clinical manifestations that recapitulate most of the
features of GSDIa seen in humans including profound
lactic acidosis [17–19]. The purpose of this paper is to
review important aspects of human GSDIa and to provide
a detailed comparison to the canine model. In addition, an
emphasiswillbeplacedonhowthecaninemodeliscurrently
being used in preclinical trials for gene therapy mediated
correction of GSDIa and how such research can contribute
to the development of new potential therapies and cures for
this and possibly also other genetic and metabolic disease
conditions.
2. GeneticBasisfor GSDIaand Diagnosis
The G6Pase complex is located in the inner membrane of the
endoplasmic reticulum. In order for glucose-6-phosphate to
be hydrolyzed to glucose, G6P must be transported through
a bidirectional translocase to the catalytic site. GSDIa occurs
when the G6Pase is not produced or when mutations
result in a nonfunctional enzyme. The gene encoding the
catalytic unit was identiﬁed in band q21 of chromosome
17 in humans [20]. Over 85 diﬀerent mutations causing
GSDIa have been described in humans, for which the typical
metabolic disturbances are fairly consistent [20–24].
The gene for the catalytic unit of the G6Pase complex
in canines has been identiﬁed and demonstrates signiﬁcant
homology when compared to humans, mice, and rats [18].
The DNA sequence contains 2346bp with a 5  untranslated
region of 87bp, an open reading frame of 1071bp, and a 3 
untranslated region of 1185bp [18, 19]. The open reading
frame encodes a 357 amino acid sequence with 91.3%
homology to the 357 amino acid sequence encoded by the
human gene [18]. The speciﬁc mutation in aﬀected dogs is
a guanine to cytosine transversion at nucleotide position 450
(G450C) [18]. This results in substitution of a methionine by
isoleucine at codon 121 (M121I) [18]. Of note, the location
of the canine mutation is very close to a known human
mutation in exon 4 of the gene and subsequent transfection
studies have proven that the mutant G6Pase has 15 times less
enzyme activity than normal [18–24].
Currentbreedingcoloniesofthecaninemodeloriginated
fromMaltesedogsexpressingthecarrier(heterozygous)state
for this naturally occurring mutation [19]. These Maltese
dogs were eventually cross-bred to normal (wild-type)
Beagles to help increase the average size of the individual
dogs and consequently the average litter size. As in humans,
only dogs homozygous for the M121I mutation demonstrate
the overt clinical manifestations of GSDIa [18, 19].
Genetictestingcanbeeasilyperformedonbloodorsaliva
from dogs using PCR and direct sequencing of the exon
as previously described (Figure 1(a)). In addition, digestion
with the restriction enzyme NcoI can be used to distinguish
aﬀected, carrier, and wild-type dogs. Since the restriction
enzyme cannot cut the mutated sequence, aﬀected (−/−)
dogs have a larger fragment compared to wild-type dogs
(Figure 1(b)).
3.Metabolic DisturbancesinGSDIa
Glucose is the primary energy source for most mammalian
cells, and its metabolism is tightly regulated to guarantee
that a suﬃcient supply is available to glucose-dependent
organs, particularlythe brain. Glucosecan be madeavailable
from two sources: absorption of dietary glucose from the
intestine and release of glucose from organs such as the
liver or kidney. Early in fasting, the majority of endogenous
glucose is generated by glycogenolysis where glycogen in the
liverisconvertedtoG6Pundertheregulationofdebranching
enzyme, hepatic glycogen phosphorylase, and phosphorylase
kinase. With more prolonged fasting, endogenous glucose is
generated by gluconeogenesis from certain substrates such as
amino acids, lactate, and glycerol. Both processes generate
G6P which must then be dephosphorylated in order to
transport glucose out of the cell (Figure 2(a)). The enzyme
responsible for this is G6Pase alpha. Alterations in quantity,
location, or activity of G6Pase such as those seen in type
I glycogen storage diseases eﬀectively result in a lack of all
endogenous glucose production and severe hypoglycemia
develops during periods of fasting (Figure 2(b)).
The high concentrations of G6P generated in GSDIa
are ultimately shunted into alternative pathways caus-
ing the classic triad of hyperlipidemia, hyperuricemia,Journal of Biomedicine and Biotechnology 3
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Figure 1: PCR sequencing and restriction digest for the canine mutation. (a) Sequencing chromatogram of the mutation region showing
the G450C transversion on both alleles of an aﬀected dog (−/−) and on one allele in a heterozygote (+/−). (b) Ncol digest after ampliﬁcation
of the target region resulting in cutting of the wild-type alleles (+/+), cutting of one allele in the heterozygote (+/−), and larger undigested
bands from both alleles in the homozygous dog (−/−).
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Figure 2: Outline of endogenous glucose production pathways. EC = extracellular, IC = intracellular. (a) Normal pathway and function of
G6Pase. (b) Alterations seen with deﬁciency of G6Pase (GSDIa) include lack of dephosphorylation of G6P and shunting of excess G6P to
produce glycogen and lactate.
and hyperlactatemia. Elevated lactate concentrations result
from shunting down the glycolytic pathway resulting in
a metabolic acidosis. Hyperlipidemia is a result of increased
synthesis of triglycerides from shunting to acetyl CoA, inhi-
bition of carnitine palmitoyltransferase I by malonyl CoA,
and decreased lipid serum clearance. Shunting of G6P into
thepentose phosphatepathwayand increased degradation of
adenine nucleotides result in increased uric acid production.
Competitive inhibition of uric acid excretion by lactate
results in decreased renal clearance.
As hypoglycemia develops in GSDIa, persistent alter-
ations in several glucoregulatory hormones occur, most
notably increased glucagon levels and decreased insulin
levels. There may be alterations in epinephrine or cortisol as
well, and this stimulation continues to worsen the metabolic
alterations. If dietary glucose is available on a relatively
constant basis as observed in many treated GSDIa patients,
glycogen degradation and gluconeogenesis decrease, and
metabolic abnormalities are expected to diminish.
4.Pathology, ClinicoPathologic Findings,
andClinicalM anif estatio nso fGSDI a
4.1. Without Treatment. T y p eI aG S Di sad i s e a s et h a ta ﬀects
approximately 1 in 100,000 individuals. The disease was ﬁrst
describedbyvonGierkein1929,butitwasalmostuniversally
fatal marked by severe hypoglycemia, growth retardation,
and life threatening acidosis prior to the introduction of
continuous glucose therapy in 1971 [25–27]. While continu-
ous feeds through a nasogastric or gastrostomy tube allowed4 Journal of Biomedicine and Biotechnology
children with this disease to survive, any interruption of
the feeds resulted in rapid onset of hypoglycemia. Seizures
and deaths related to hypoglycemia remained common until
uncooked cornstarch (UCCS) therapy was introduced in
1982 [4, 5, 28, 29]. As a result of these dietary interven-
tions, the prognosis for humans with GSDIa has improved
dramatically, but complications including metabolic acidosis
due to a persistent elevation in blood lactate levels, hep-
atic adenoma rarely leading to hepatocellular carcinoma,
chronic progressive kidney disease, gout, osteoporosis, and
pulmonary hypertension remain common in adolescent and
adult patients [7, 9–13].
There are little data about completely untreated (e.g.,
no dietary supplementation) dogs with GSDIa. The canine
disease was originally described in two untreated puppies
that died or were euthanized at about 47 days of age (about
the time they would have been expected to begin weaning),
and the authors are not aware of any reports of any untreated
dogs having lived past this age [17] .T h es a m el i t t e rh a d
included a mummiﬁed fetus, another littermate that died
at about 35 days of age, and one clinically healthy puppy
that weighed almost 2.5 times the aﬀected puppies at the
same age. There are no published reports of antemortem
diagnostic testing performed in these two dogs, but the
medical history included notes of markedly reduced growth
rateandpoorbodycondition,mentaldepression,abdominal
distension, hepatomegaly, and nephromegaly.
Gross pathologic ﬁndings from necropsy of both pup-
pies included emaciation, enlarged, pale and friable livers,
enlarged and pale kidneys with white lines present along
the renal crest and at the corticomedullary junction, mild
hydrocephalus, and enlarged, rounded spleens [17]. Histo-
logic lesions were similar in both puppies. There was severe,
diﬀusevacuolarchange in hepatocytes resulting in distortion
of normal hepatic architecture. In the kidneys, there was
evidence of interstitial ﬁbrosis, and moderate vacuolar
changeintubularepithelialcells.Cytoplasmfromvacuolated
hepatocytes and renal epithelium demonstrated positive
periodic acid-Schiﬀ (PAS) staining (consistent with glycogen
storage) but were negative for Sudan staining (indicating
that the vacuoles did not contain fat). Mineralization was
also noted in the kidney, especially in proximity to the
renal pelvis and along the corticomedullary junction, and
also in the lung within the alveolar septa. Other changes
included extramedullary hematopoiesis in the spleen and
smallfolliclesinthethyroidglandthatweredevoidofcolloid.
Glycogen, G6Pase, and a few other metabolic enzyme
levels in the liver and kidney tissue of these two aﬀected pup-
pies were compared to control puppies that died at similar
ages from other diseases. Glycogen levels were signiﬁcantly
increased in the aﬀected puppies whereas G6Pase levels were
severely reduced. There was no signiﬁcant diﬀerence noted
in the other tested metabolic enzymes.
4.2. With Dietary Intervention. Although current dietary
treatmentprotocolshavedramaticallyimprovedsurvivaland
qualityoflifeforhumanswithGSDIa,theunderlyingG6Pase
deﬁciency remains. People with glycogen storage disease
remain susceptible to rapid development of hypoglycemia
should therapy be interrupted. Most adults continue to
require 5-6 doses of UCCS per day to maintain good
metabolic control, although review of actual patient intakes
have demonstrated that some adult patients receive less
frequent doses of UCCS [7, 11, 30, 31]. In addition,
complications of the uncorrected enzyme deﬁciency and
metabolicchangesassociatedwithdietary interventions area
source of signiﬁcant morbidity during and after adolescence
[10–13].
In the canine population, all untreated dogs with GSDIa
die and all long-term survivors are part of gene therapy
research trials [17–19, 32–34]. Attempts at maintaining dogs
using nutritional therapies similar to those used in aﬀected
humanshaveprovenunsuccessful,andlong-termnutritional
therapy has not been reported to date in the literature. In our
experience,nutritionaltherapywasabletokeepadogaliveto
5–1/2 months, but chronic acidosis, respiratory distress, and
intermittent hypoglycemia remained problematic even with
feeds administered every 30 minutes [34]. Hyperlipidemia
and hepatomegaly worsened over time, and ultimately this
dog developed severe hepatic lipidosis and pancreatitis [34].
Notably, unlike the aforementioned murine model, dogs
with GSDIa continue to have fasting hypoglycemia after
weaning [30, 32]. Although the overall success of nutritional
intervention seems to be lower for the canine model than
for human patients at the current time, puppies with GSDIa
appear to have similar pathologic changes and many of
the same clinical manifestations of disease that are seen in
human GSDIa patients [17–19, 25–27, 29, 32–34].
Fetal mortality and whelping complications are extreme-
ly common in canine GSDIa. Stillbirth, fetal resorption, and
mummiﬁcation are all frequently encountered problems in
litters from heterozygote parents, and up to 50% of GSDIa
puppies have been reported to be stillborn or die in the
perinatal period [19]. Aﬀected puppies are hypoglycemic at
birth, and can struggle with nursing [32]. Without interven-
tion, almost all aﬀected puppies die within an hour of birth.
With initiation of feeds, hepatomegaly rapidly develops. In
order to prevent severe hypoglycemia and seizures, puppies
must be manually feed every 30 minutes, but they continue
to struggle with poor growth rates, lower activity levels,
decreased mental alertness, and delayed development of
neurologic reﬂexes [17, 19]. Severe hypoglycemia to less than
35mg/dL develops within 60 minutes of a feed if therapy
is interrupted, and biochemical abnormalities in aﬀected
puppies include persistently elevated levels of lactate, uric
acid, cholesterol, and triglycerides [19, 34].
In puppies that have died (or were euthanized) despite
receiving nutritional support for their GSDIa, pathologic
lesions have been identiﬁed that were similar, but not
identical, to those of untreated puppies [19, 34]. All puppies
had gross hepatomegaly ranging from mild to severe, but
renomegaly was not noted [19, 34]. Histopathology revealed
marked hepatocellular vacuolar changes with distortion of
normal architecture and positive PAS and oil-red-O staining,
demonstratingthepresenceofbothglycogenandfat[19,34].
Vacuolar changes suggestive of glycogen storage were also
seen in renal tubular epithelium, and glomerular changesJournal of Biomedicine and Biotechnology 5
were also observed in the slightly older (>30 days) dogs [19].
One potential reason for the limited success of dietary
interventions in puppies with GSDIa is the lack of infor-
mation about the speciﬁc nutritional needs of these dogs.
Aﬀected neonates have been managed with a variety of
dietary protocols that included allowing for nursing but pro-
vided additional carbohydrate supplementation in the form
ofmilkreplacerformula,glucosepolymers,ordextrosegiven
orally,orbyparenteraladministrationofdextrosecontaining
ﬂuids [19, 32, 34]. Postweaning untreated, aﬀected puppies
and adults have been managed with frequent feedings
(q2–4 hours) of commercially available puppy foods with
additional carbohydrate support in the form of milk replacer
formula, glucose polymers, UCCS, or dextrose given orally
at frequent intervals (q30min to q4 hours) [19, 32, 34].
Protocols are still being developed to help identify the
best delivery methods (i.e., oral feeding, gavage feeding,
or various types of feeding tubes) and optimal nutritional
proﬁlestoprovideadequateglucosewithoutsacriﬁcingother
important nutrients. It is hoped that with more experience
and better treatment protocols aﬀected puppies from future
litters will have less developmental problems and improved
survival to adulthood.
Because so few aﬀe c t e dd o g sh a v es u r v i v e dt oa d u l t h o o d ,
it is diﬃcult to determine if many of the long-term com-
plications seen in human patients will be recapitulated by
this model. Hopefully, as the dog colonies grow and better
nutritional protocols are developed, a group of aﬀected adult
dogs can be followed to document and characterize the
complications that occur in this model.
4.3. Heterozygotes. Although only dogs that are homozygous
for the M121I mutation exhibit the overt clinical manifes-
tations of GSDIa, there are some data from our colony to
suggestthatdogsthatareheterozygousforthemutationhave
subtle manifestations of the disease. Heterozygote dogs have
∼50% of the G6Pase activity of wild-type individuals [34].
They are able to tolerate a 12-hour fast with no apparent
clinical signs and without hypoglycemia [34]. However, after
a 12-hour fast these dogs do have slightly elevated blood
lactate levels compared to wild-type dogs and laboratory
reference standards [34]. Liver biopsies reveal that these dogs
have mild vacuolar changes with positive PAS staining and
MRSdatafromonedogshowedabout2.9timesgreaterlevels
of glycogen in the liver than was found in a wild-type dog
[34]. These ﬁnding suggest that although heterozygote dogs
exhibit an overall normal outward phenotype, 50% of wild-
type G6Pase activity does not provide a completely normal
biochemical, physiological, or histological phenotype.
The human carrier population for various mutations
in the G6Pase gene has not been reported to exhibit any
overt pathology or complications of GSDIa. Whether the
speciﬁc abnormalities detected in our heterozygote dogs also
occur in the human population remains unknown at this
time. There are some parents of aﬀected children who have
provided anecdotal accounts of symptoms such as shaking
and weakness with fasting. These could be incidental or
could be attributed to similar subtle clinical abnormalities
related to comparatively lower levels of G6Pase.
5. Use of the CanineGSDIaModel for
PreclinicalTrials
Currently, the canine model of GSDIa is being studied
primarily as part of early stage preclinical trials of recom-
binant adeno-associated virus (AAV) vector-based therapies.
These types of therapy oﬀer great promise for the treatment
of GSDIa since they target the underlying problem rather
than just palliating some of the clinical eﬀects of G6Pase
deﬁciency.
With the ability to generate large numbers of aﬀected
animals quickly, the murine model of GSDIa has provided
a useful platform to prove the concept of gene therapy
f o rc o r r e c t i o no fG S D I aa n dt oc o m p a r et h ee ﬃcacy of
various types of vectors [33, 35, 36]. Gene therapy has
mediated prolonged survival, sustained correction of glucose
homeostasis and normalization of triglycerides, cholesterol,
and uric acid in mice using a variety of diﬀerent vectors,
although substantial variation in eﬃcacy and speciﬁc eﬀects
of the diﬀerent vectors has been identiﬁed [33, 35–38]. The
lack of ability to address all of the clinical manifestations
(e.g., lactic acidosis) of GSDIa in this model and the lack
of ability to address long-term safety and eﬃcacy due to the
short overall lifespan of the mice demonstrate the need for
additional studies in a diﬀerent model.
The ﬁrst reported results of gene therapy in the canine
model utilized an AAV vector administered between 3-
4d a y sa f t e rb i r t h[ 32]. Puppies that received the vector
demonstrated increased G6Pase activity in the liver and
d e c r e a s e dg l y c o g e nc o m p a r e dt ou n t r e a t e d ,a ﬀected dogs.
Some dogs also had improvement in blood glucose, triglyc-
eride, cholesterol, and lactate levels after a three-hour fast
comparedtountreated,aﬀecteddogsataleastonetimepoint
after vector administration. When compared to carriers or
wild-type dogs; however, these treated dogs demonstrated
only partial improvements in biomarker levels and all
succumbed to a GSDIa-related medical crisis between 20–86
days of age.
Later reports indicated that gene therapy utilizing an
AAV2/8 vector signiﬁcantly improved survival in three dogs
compared to untreated controls and the dogs from the
previous report by Beaty et al. [32, 33]. All three dogs
survived passing 11 months of age. In addition to improved
survival, treated dogs were able to maintain normal blood
glucose levels during a fasting period of at least 2 hours
(longer times are not reported) starting after 1–6 month
(s) of age. While treated dogs still required frequent feeding
(q6–10hr) compared to normal dogs, they did not require
additional carbohydrate supplementation. Glycogen and fat
storage in the liver was reduced, and G6Pase activity was
increased compared to values from untreated dogs and were
comparable to levels reported in carrier dogs which showed
no overt clinical signs of GSDIa. While lactate levels after a
2-hour fast were signiﬁcantly improved in the treated dogs
compared to untreated controls, they remained well above
normal laboratory standards for dogs (>2.1mmol/L).
Several dogs from a colony at the University of Florida
have also been treated with gene therapy utilizing AAV
vectors. The ﬁrst dog was treated with an AAV2/8 vector on6 Journal of Biomedicine and Biotechnology
postnatal day 1 [34]. Two dogs from each of two subsequent
litters have received gene therapy with AAV vectors at
postnatal days 1 or 2. Four of ﬁve treated dogs demonstrated
an ability to maintain normal glucose and lactate levels
during a two-hour fast at one month after treatment. The
other dog did not receive the entire IV dose of vector due to
subcutaneous extravasation and remained unable to tolerate
a 2-hour fast.
While the dogs clinically improved after the initial dose
of gene therapy, this level of correction was not sustained
in any of these dogs. By two months of age, fasting glucose
concentrations fell to levels similar to those of an untreated
puppy and elevated lactate concentrations were consistently
seen with fasting. In addition, growth curves for these dogs
remained more similar to untreated controls than to wild-
type puppies during the ﬁrst few months of life. Similar
results are reported in mice, in which intravenous delivery
of AAV vector to deliver the gene of interest to neonates did
not result in sustained correction.
Due to lack of sustained correction, the ﬁrst dog was
treated again at 20 weeks of age with a second dose
of gene therapy delivered by an AAV2/1 vector injected
into the portal vein [34]. This resulted in a sustained
partial correction of the G6Pase deﬁciency and a dramatic
improvement in the metabolic status of the dog. One
month after treatment with the AAV2/1 vector, dextrose
supplementation was discontinued and this dog continues
to do well clinically three years later receiving a mixture
of canned and dry preparations of a commercially available
dog food supplemented with UCCS oﬀered every 4–6 hours.
Serial fasting studies show the best response at two months
after treatment, when fasting blood glucose and lactate
levels were normal for greater than 5 hours and still close
to normal at 9 hours into the fast. The response was
somewhat diminished at 15 months after injection, but in
contrast to dogs described in prior reports, this dog has
consistently maintained normal blood glucose and lactate
levels throughout fasting periods of 2–4 hours. Liver biopsies
collected at 30 months had greater G6Pas activity and much
less glycogen and fat accumulation than biopsies from an
untreated control; however, they were still abnormal when
compared to wild-type controls.
Thesecondandthirddogsweredoingwellclinicallyuntil
developing signs of acute respiratory distress at 74 days of
age.Dyspneaandhypoxemiadevelopedrapidly,andthedogs
died from this complication despite aggressive critical care.
Necropsy and infectious disease testing revealed severe viral
pneumoniacausedbyCanineadenovirus-2(whichisdistinct
from, and unrelated to, the adeno-associated virus used as a
vector).Thedeathofthesedogswasnotdeemedtoberelated
to the gene therapy.
Two other dogs from our colony have recently been
treated and have shown results similar to the ﬁrst dog. They
received their second doses of AAV vector at approximately
10 weeks of age. Both dogs are clinically healthy with no
glucose supplementation at this time. However, these dogs
are currently only ﬁve months old, so it is too early to
determine if there will be a sustained partial correction of
their condition.
Overall, the collective work of the two centers currently
using the canine model of GSDIa in preclinical trials of AAV
vector-mediated gene therapy have demonstrated signiﬁ-
cant improvements in biomarker levels and histopathologic
abnormalities, and dramatically improved survival times for
dogs treated with gene therapy compared to controls [33,
34].
6. Challenges Involvedin Use of
the CanineGSDIaModel
Despite a number of advantages that the canine model of
GSDIa has over the murine model in studies evaluating
potential therapies for human GSDIa, there are also some
signiﬁcant challenges involved in the use of the canine model
for preclinical studies.
One challenge is generating a high number of aﬀected
dogs enough to make valid comparisons between diﬀerent
types of therapies. Aﬀected dogs have not been reported to
survive to adulthood without treatment, and so all breeding
animalstodatehavebeencarriers(heterozygotes).Duetothe
reproductive biology of the dog, regulatory considerations,
fertilityissuesrelatedtoGSDIa,andtheexpectationthatonly
about 25% of oﬀspring will be homozygotes; each breeding
female in the colony produces an average of one aﬀected
puppy per year. Perinatal death is also an issue if dogs are
allowedtowhelp,andupto50%mortalityhasbeenreported
i nG S Dd o g sb o r nn a t u r a l l y[ 19]. All litters in the colony at
the University of Florida have been delivered by Cesarean
section allowing 100% survival of aﬀected puppies since
dogs are immediately resuscitated with glucose upon birth,
but this increases the cost and labor associated with having
puppies with this disease.
The length of time needed to generate a reasonably
sized dog colony presents some additional challenges. Each
aﬀected or carrier dog that is part of the colony needs
housing,food,andintensive,around-the-clockcare.Aﬀected
dogs can also experience medical crises with little warning.
One refused feeding or an episode of vomiting or diar-
rhea can lead to severe hypoglycemia and lactic acidosis.
Severe hypoglycemia can result in lethargy, weakness, loss
of consciousness, or seizures. Lactic acidosis can cause or
exacerbate anorexia, nausea, and vomiting which further
complicates oral glucose administration. Most medical crises
in GSDIa dogs require immediate additional oral glucose
supplementation or parenteral administration of dextrose.
Due to the fragility of GSDIa dogs, there is a need for on-
call veterinary support at all times. The coordinated involve-
ment of researchers, caretakers, and veterinary specialists is
required to optimize the growth and health of the colony
and the GSDIa gene therapy research. These factors also
contribute to making the canine GSDIa model ﬁnancially
expensive to use.
Another major challenge in current GSDIa gene therapy
research using the canine model is the lack of deﬁned
protocols proven to be eﬀective for nutritional support of
aﬀected dogs. Currently, nutritional supplementation has
not been reported to provide the same survival beneﬁt toJournal of Biomedicine and Biotechnology 7
dogs with GSDIa that it has for people [4–11, 13]. The
lack of comparable beneﬁts so far may be due in part to a
relative lack of experience treating dogs with GSDIa and the
natural challenges that exist when translating human GSDIa
nutrition protocols to a canine model. For example, growing
dogs typically get a much higher percentage of energy from
fats and proteins than do humans [39]. Since protein and
fats cannot be used as a precursor of gluconeogenesis in
dogs with GSDIa, aﬀected dogs must necessarily receive a
carbohydrate-heavy diet, which includes excessive amounts
of carbohydrate compared with what normal dogs require. It
is, therefore,diﬃculttoprovideacompleteandbalanceddiet
without overfeeding.
7. FutureDirections
One target of future research will be improvement of
nutritional support protocols to better meet the speciﬁc
needs of dogs with GSDIa. Use of well deﬁned nutritional
support protocols that mimic protocols used in human
GSDIa patients, but which are tailored to the speciﬁc needs
of the canine model, will provide a comparison group
for future preclinical trials of curative therapies, that is, a
closer analogue to the human situation. Better nutritional
management will also likely allow for a reduction in the cost
ofcareforthesedogs,improvesurvivaltimes,andpotentially
allow aﬀected dogs to participate in the breeding program
which would signiﬁcantly increase the number of aﬀected
and carrier puppies per litter.
Further work to identify an optimal protocol for gene
therapy in GSDIa dogs including the best vector serotype,
gene promoter, and timing and route of vector delivery
hold great promise for developing a treatment that can
eventually be translated for use in human GSDIa patients.
Additional preclinical trials involving stem cell therapy or
administration of novel longer-acting starches in this model
may also yield valuable information about other potential
therapeutic options for GSDIa.
Lastly, although GSDIa is a rare condition, preclinical
trials of gene therapy and stem cell therapy to treat GSDIa in
dogs will also serve as a useful model for testing the potential
of these treatments for other hepatic genetic and metabolic
diseases. There are over 30 diﬀerent liver related disorders
due to single-point mutations [40]. Many of these disorders
require treatment with therapeutic agents that are expensive
or diﬃcult to obtain, and the eﬃcacy of new treatment
modalities can only be assessed through long-term studies
and liver biopsies. In contrast, blood glucose and lactate
serve as useful and inexpensive biomarkers for testing the
success of therapy for GSDIa in canines and pretreated or
control dogs can be managed with carbohydrate support.
Thus, testing the feasibility and eﬃcacy of new therapies
in this model may then allow for translation to curative
treatments for other genetic liver diseases.
8. Conclusion
The canine model of GSDIa has a similar genetic and
underlying metabolic basis compared to GSDIa in humans.
Clinicopathologic, pathologic, and clinical manifestations of
GSDIa in this model are also very similar to what is observed
in humans, including lactic acidosis which is not a consistent
feature of the murine model. It remains to be seen whether
long-term complications of GSDIa seen in humans treated
with the current standard of care for nutritional supplemen-
tation are also features of the canine disease. More complete
recapitulation of the clinical manifestations of GSDIa in
humans, larger size, and longer life span of dogs with GSDIa
relative to mice are all advantages for use in preclinical
trials of new treatments. However, there are some signiﬁcant
challenges as well such as the time, labor, and cost involved
in generating useful numbers of aﬀected dogs. Despite these
challenges, preclinical trials have already demonstrated the
potential for gene therapy to establish prolonged partial
correction of the underlying G6Pase deﬁciency in canine
GSDIa.Withlargercolonies,improvednutritionalprotocols,
and additional preclinical trials, the canine GSDIa model
shouldprovidevaluableinformationrelatingtooptimization
of gene therapy protocols and evaluation of other therapies
such as stem cell therapy or novel starches. Eventually,
research involving dogs with GSDIa may help to identify
curative therapies which can then be translated to human
patients with GSDIa or other hepatic genetic or metabolic
diseases.
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